President Issues Executive Order Amending Duties on Synthetic Opioids from China
In a recent executive order issued by the President of the United States, amendments have been made to the Executive Order of February 1, 2025, specifically targeting the synthetic opioid supply chain originating from the People’s Republic of China. The order, authorized under various Acts including the International Emergency Economic Powers Act and the National Emergencies Act, aims to address the ongoing crisis of synthetic opioids entering the country.
One of the key changes implemented by the new executive order is the modification of subsection (g) of section 2 of the original order. This amendment now includes provisions for duty-free de minimis treatment under certain conditions outlined in the order. However, this treatment will cease to be available for covered articles once the Secretary of Commerce notifies the President that adequate systems are in place to collect tariff revenue applicable to these articles.
The general provisions of the order emphasize that it should not impair or affect the authority granted by law to executive departments or agencies. Additionally, it specifies that the order must be implemented in accordance with applicable law and subject to the availability of appropriations. Furthermore, it clarifies that the order does not create any enforceable rights or benefits against the United States or any of its entities.
This executive order signifies the government’s continued efforts to combat the influx of synthetic opioids from China, which have contributed to the widespread opioid crisis in the country. By implementing stricter duties and regulations on these substances, the administration aims to mitigate the adverse effects of these drugs on public health and safety.
The issuance of this executive order on February 5, 2025, underscores the administration’s commitment to addressing the synthetic opioid crisis and protecting the American people from the harmful effects of these substances. The amendments made to the original order demonstrate a proactive approach to tackling the issue at its source and ensuring the enforcement of necessary measures to combat the illicit supply chain.
In conclusion, the amended executive order reflects the government’s determination to prioritize national security and public welfare by targeting the importation of synthetic opioids from China. By enacting these changes, the administration seeks to strengthen regulatory measures and enhance enforcement mechanisms to safeguard the country from the devastating impact of these dangerous substances.
